BPA for strensiq

Ended Awarded Last action

Contract number
36E79722A0026
Awardee
Awarding agency
Task orders
1 $104,650 obligated

Award facts

Opportunity
  • VA797P12Q0002 Solicitation number
Combined order value
$104,650 Current and potential, with all options
Last date to order 100% complete
IDV ceiling 2% used
$4,239,517.80
Award type
Single award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The Department of Veterans Affairs National Acquisition Center established a single-award Blanket Purchase Agreement with Alexion Pharmaceuticals Inc. on September 1, 2022, with a ceiling of $4,239,517.80 and an ultimate completion date of July 24, 2026, against the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB).

The BPA procures Strensiq, a specialized injectable medication used to treat perinatal/infantile- and juvenile-onset hypophosphatasia, a rare genetic disorder. Performance occurs at Alexion's Boston, Massachusetts facility and supports delivery to VA medical centers and clinics nationwide.

Recent BPA-call activity includes a July 21, 2026 order from Veterans Integrated Service Network 5 for Strensiq 80 mg with a ceiling value of $104,650.40 and completion date of July 23, 2026, with performance in Carrollton, Texas. Delivery orders have been issued throughout 2023, 2024, and 2025 to Veterans Integrated Service Networks across the VA system, ranging from approximately $70,658 to $1.25 million, supporting continuity of care for eligible veterans.

Task orders

Task order Ordering agency Obligated Awarded
Strensiq 80 MG 36C24526N0739 Veterans Integrated Service Network 5 (VHA) $104,650

Transactions

Action Obligated Date
Legal Contract Cancellation P00008 · This modification is issued to cancel BPA 36E79722A0026 in its entirety as the parent FSS contract 36F79718D0355 has expired. A new BPA will be issued under the… $0
Supplemental Agreement for work within scope P00007 · 2026 public law pricing updates. $0
Exercise an Option P00006 · This modification is issued to exercise option year 3 on BPA 36E79722A0026. $0
Supplemental Agreement for work within scope P00005 · 2025 public law pricing updates $0
Exercise an Option P00004 · Exercise option year 2 for BPA 36E79722A0026. $0
Supplemental Agreement for work within scope P00003 · 2024 public law pricing updates $0
Exercise an Option P00002 · Exercise option year 1 on BPA 36E79722A0026. The period of performance is 09/1/2023 - 08/31/2024. $0
Supplemental Agreement for work within scope P00001 · 2023 public law pricing updates $0
Original award $0

Quick answers

Who was awarded contract 36E79722A0026?

36E79722A0026 was awarded to Alexion Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on September 1, 2022.

How much is contract 36E79722A0026 worth?

Orders under 36E79722A0026 have obligated $104,650. 36E79722A0026's own ceiling is $4,239,518.

How many orders have been placed under contract 36E79722A0026?

1 order has been placed under 36E79722A0026, the latest on July 21, 2026.

Who can order from contract 36E79722A0026?

36E79722A0026 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

Is contract 36E79722A0026 under another contract?

Yes. 36E79722A0026 is a blanket purchase agreement under 36F79718D0355, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36E79722A0026 competed?

The extent of competition for 36E79722A0026 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV